+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Blepharitis - Pipeline Review, H1 2020

  • ID: 5007667
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 61 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Azura Ophthalmics Ltd
  • Hovione FarmaCiencia SA
  • Merck & Co Inc
  • NicOx SA
  • Novaliq GmbH
  • MORE
Blepharitis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Blepharitis - Pipeline Review, H1 2020, provides an overview of the Blepharitis (Ophthalmology) pipeline landscape.

Blepharitis is an inflammation of the eyelids, usually caused by an excess growth of bacteria that is ordinarily found on the skin, blockage of the eyelid's oil glands, and occasionally allergies. Blepharitis signs and symptoms include watery eyes, red eyes, itchy eyelids, sensitivity to light. Treatment includes antibiotics, lubricating eye drops and steroid eye drops or ointments.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Blepharitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 7 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aerie Pharmaceuticals Inc
  • Azura Ophthalmics Ltd
  • Hovione FarmaCiencia SA
  • Merck & Co Inc
  • NicOx SA
  • Novaliq GmbH
  • MORE
  • Introduction
  • Report Coverage
  • Blepharitis - Overview
  • Blepharitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Blepharitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Blepharitis - Companies Involved in Therapeutics Development
  • Aerie Pharmaceuticals Inc
  • Azura Ophthalmics Ltd
  • Formosa Pharmaceuticals Inc
  • Hovione FarmaCiencia SA
  • Merck & Co Inc
  • NicOx SA
  • Novaliq GmbH
  • Premark Pharma GmbH
  • Quorum Innovations LLC
  • Surface Pharmaceuticals Inc
  • Tarsus Pharmaceuticals Inc
  • Blepharitis - Drug Profiles
  • (doxycycline + omega 3 fatty acid) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APP-13002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZRBL-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZRBL-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fluticasone propionate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HY-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NOV-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PMP-2207 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Qi-402 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Dry Eye and Meibomian Blepharitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • solithromycin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TP-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Blepharitis - Dormant Projects
  • Blepharitis - Product Development Milestones
  • Featured News & Press Releases
  • Dec 19, 2019: Nicox’s NCX 4251 meets primary endpoint in phase 2 blepharitis trial and shows promising efficacy in dry eye disease
  • Sep 27, 2019: Nicox completes enrolment of NCX 4251 phase 2 trial with top-line results on track for Q4 2019
  • Mar 19, 2019: Nicox initiates phase 2 trial of NCX 4251 in Blepharitis
  • Mar 18, 2019: Nicox poster presentation at AGS 2019 Annual Meeting Discloses preclinical data for NCX 4251, a novel blepharitis therapy
  • Mar 12, 2019: Nicox announces presentations including drug candidate NCX 4251 at upcoming scientific conferences
  • Jan 29, 2019: Nicox announces U.S. FDA acceptance of Investigational New Drug Application for NCX 4251 phase 2 trial in Blepharitis
  • Jan 05, 2017: Nicox provides clinical and regulatory update for NCX 4251 in blepharitis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Blepharitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Blepharitis - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
  • Blepharitis - Pipeline by Azura Ophthalmics Ltd, H1 2020
  • Blepharitis - Pipeline by Formosa Pharmaceuticals Inc, H1 2020
  • Blepharitis - Pipeline by Hovione FarmaCiencia SA, H1 2020
  • Blepharitis - Pipeline by Merck & Co Inc, H1 2020
  • Blepharitis - Pipeline by NicOx SA, H1 2020
  • Blepharitis - Pipeline by Novaliq GmbH, H1 2020
  • Blepharitis - Pipeline by Premark Pharma GmbH, H1 2020
  • Blepharitis - Pipeline by Quorum Innovations LLC, H1 2020
  • Blepharitis - Pipeline by Surface Pharmaceuticals Inc, H1 2020
  • Blepharitis - Pipeline by Tarsus Pharmaceuticals Inc, H1 2020
  • Blepharitis - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Blepharitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aerie Pharmaceuticals Inc
  • Azura Ophthalmics Ltd
  • Formosa Pharmaceuticals Inc
  • Hovione FarmaCiencia SA
  • Merck & Co Inc
  • NicOx SA
  • Novaliq GmbH
  • Premark Pharma GmbH
  • Quorum Innovations LLC
  • Surface Pharmaceuticals Inc
  • Tarsus Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll